CTOs on the Move

Cullinan Oncology

www.cullinanoncology.com

 
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Cullinan Oncology raised $98.5M on 06/04/2020

Similar Companies

Scioto Biosciences

Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics.

BioRestorative

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person`s own) cultured mesenchymal stem cells collected from the patient`s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient`s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient`s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Millennium Pharmaceuticals Inc

Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering

BioSciConcepts

BioSciConcepts is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UVJ technology

UVJ technology is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.